Cubosomal Betamethasone-Salicylic Acid Nano Drug Delivery System for Enhanced Management of Scalp Psoriasis
Rodayna Atef Shalaby,Omaima El-Gazayerly,Mohammed Abdallah
DOI: https://doi.org/10.2147/IJN.S345430
IF: 7.033
2022-04-13
International Journal of Nanomedicine
Abstract:Rodayna Atef Shalaby, 1 Omaima El-Gazayerly, 2 Mohammed Abdallah 2 1 Department of Pharmaceutics and Industrial Pharmacy, School of Pharmacy, New Giza University, Giza, Egypt; 2 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt Correspondence: Omaima El-Gazayerly, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt, Tel +2-01005840254, Email Introduction: Betamethasone dipropionate (BD), a potent corticosteroid, and salicylic acid (SA), a keratolytic agent, have been used in combination to treat scalp psoriasis; however, undesirable side effects associated with their prolonged topical use are inevitable. In this study, BD and SA were loaded into cubosomes, a nanoparticulate system with outstanding biocompatibility, bio-adhesivity and penetration power. Methods: Design of experiments (DOE) was utilized to prepare thirteen different cubosomal dispersions by emulsification technique using glycerol monoolein (GMO) as a lipid phase and Poloxamer 407 (P407) as a surfactant, sodium carboxymethyl cellulose (SCMC) was added to enhance the dispersions' rheological properties. The thirteen dispersions were in-vitro characterized for their particle size, polydispersity index (PDI), zeta potential, BD and SA content and rheological behaviour. The desirability of an optimized formula (OF) was set to the smallest particle size, lowest zeta-potential and highest viscosity. The OF was in-vitro characterized for the same parameters in addition to transmission electron microscope imaging and in-vitro drug release. The OF's anti-psoriatic activity was evaluated in-vivo using an imiquimod-induced psoriasis model. Results: The OF achieved a particle size of 197.4 ± 9.47 nm, a PDI of 0.443 ± 0.025, a zeta potential of − 44.4 ± 0.141mv, BD content of 105.85 ± 2.290%, SA content of 88.855 ± 2.920% with shear-thinning rheological behaviour and completed in-vitro drug release within 2– 3 hours. The in-vivo studies confirmed the cubosomes' higher anti-psoriatic efficacy over the commercial product with lower changes in ear thickness, spleen to body weight ratio, psoriasis area severity index score and improved histopathological findings. Conclusion: The developed BD SA-loaded cubosomes exhibit promising anti-psoriatic activity attributed to its nano-size and unique lipid content, with enhanced skin penetration and modified rheological properties; increasing the formulation's in-contact duration with the scalp resulting in lower application frequency and thus reduced BD and SA associated side effects. Keywords: betamethasone dipropionate, salicylic acid, cubosomes, psoriasis Psoriasis, a chronic inflammatory immune-mediated skin disorder, is characterized by the abnormal hyperproliferation of keratinocytes with a universal prevalence of 1–2%. 1 The scalp is considered one of the most involved body sites throughout the course of the disease. 2 Scalp psoriasis (SP) has been reported in around 80% of the worldwide psoriasis cases 3 and 61.6% of patients with psoriasis registered in the Kasr Al-Ainy psoriasis unit in Egypt. 4 The aetiology of SP remains unknown with a highly variable clinical presentation that ranges from mild fine scaling to severe thickened crusted plaques covering the entire scalp. 5 The leading presenting symptoms of SP are usually itching, dryness and scaling in addition to the visibility of scalp lesions which contribute to the negative psychological impact on the patients, besides the possibility of potential development of cicatricial alopecia, especially in the chronically affected scalp areas. 6 For decades, topical corticosteroids remained the mainstay in the management of SP, however, keratolytic agents, vitamin D analogues, retinoids, dithranol as well as tar-based therapies have also been used as adjunctive treatment, such drugs have been formulated into numerous formulations such as shampoos, alcohol‐based lotions, emulsions, creams, ointments, gels and foams. 2,7 Betamethasone Dipropionate (BD) is one of the most widely used corticosteroids in the management of SP; since BD have marked anti‐inflammatory, immunosuppressive and antiproliferative actions on epidermal cell turnover. 8 However, skin atrophy, striae, rosacea, purpura, delayed wound healing, hypertrichosis and pigment alteration are among the adverse side effects associated with BD prolonged use. 9,10 On the other hand, salicylic acid (SA), a keratolytic agent, is indicated in SP because of its ability to remove scales from hyperkeratotic plaques. 11 However, SA might irritate non‐hyperkeratotic skin and it -Abstract Truncated-